T
48
3
TXN
49
-6
RCL
88
-2
CAH
60
2
CHD
48
-3
EXR
59
4
JBHT
63
-5
MAT
38
-3
FRT
48
2
DG
12
2
NRG
50
-2
NWS
79
-4
CHRW
67
3
MU
32
-6
WDC
38
-3
PFG
50
-2
ROK
67
5
ETR
68
-3
SIG
47
-2
AMG
43
3
T
48
3
TXN
49
-6
RCL
88
-2
CAH
60
2
CHD
48
-3
EXR
59
4
JBHT
63
-5
MAT
38
-3
FRT
48
2
DG
12
2
NRG
50
-2
NWS
79
-4
CHRW
67
3
MU
32
-6
WDC
38
-3
PFG
50
-2
ROK
67
5
ETR
68
-3
SIG
47
-2
AMG
43
3
Financhill
Back

Allogene Therapeutics 10K Form

Sell
26

ALLO
Allogene Therapeutics

Last Price:
2.47
Seasonality Move:
-6.71%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ALLO News And Ratings

See the #1 stock for the next 7 days that we like better than ALLO

ALLO Financial Statistics

Sales & Book Value

Annual Sales: $95K
Cash Flow: $-44.54M
Price / Cash Flow: 0
Annual Sales: $2.21
Price / Book: 1.23

Profitability

EPS (TTM): -1.56000
Net Income (TTM): $-283.43M
Gross Margin: --
Return on Equity: 0%
Return on Assets: 0%

Allogene Therapeutics Earnings Forecast

Key Allogene Therapeutics Financial Ratios

  • The Research & Development expenses have been 255,698.95% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • Per Share Earnings over the last 6 years have been positive in 3 years.

Allogene Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: ALLO
CUSIP: 019770
Website: allogene.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

ALLO Technical Analysis vs Fundamental Analysis

Sell
26
Allogene Therapeutics (ALLO) is a Sell

Is Allogene Therapeutics a Buy or a Sell?